Cancer Research Technology (CRT)

Cancer Research Technology and Teva Pharmaceuticals form R&D alliance for R&D DNA damage response drugs

Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

16 September 2013

Cancer Research Technology, The Institute of Cancer Research and Merck Serono sign licensing deal on molecules that block the WNT signalling pathway

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, The Institute of Cancer Research, London, and , Merck Serono, a division of Merck KGaA, Darmstadt, Germany, have signed a licensing deal today extending a successful initial alliance to discover and develop anticancer drugs that block the WNT signalling pathway. Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, The Institute of Cancer Research, London, and , Merck Serono, a division of Merck KGaA, Darmstadt, Germany, have signed a licensing deal today extending a successful initial alliance to discover and develop anticancer drugs that block the WNT signalling pathway.

30 July 2013

Forma therapeutics and Cancer Research Technology to discover cancer drugs targeting deubiquitinating enzymes (DUBS)

Forma Therapeutics and Cancer Research Technology, Ltd. (CRT), the commercialisation company of Cancer Research UK, announced today a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes (DUBs). Forma Therapeutics and Cancer Research Technology, Ltd. (CRT), the commercialisation company of Cancer Research UK, announced today a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes (DUBs).

9 July 2013

• Health & Medicine

CRT, University of Manchester and AstraZeneca work together to seek new cancer drugs

CANCER RESEARCH TECHNOLOGY, the commercial arm of Cancer Research UK, the University of Manchester and AstraZeneca today announced two agreements to seek new cancer drugs. CANCER RESEARCH TECHNOLOGY, the commercial arm of Cancer Research UK, the University of Manchester and AstraZeneca today announced two agreements to seek new cancer drugs.

14 June 2013

Cancer Research UK and CRT collaborate with Abcodia to discover and develop tests for early diagnosis of cancer

CANCER RESEARCH UK and its commercial arm, Cancer Research Technology (CRT), have joined forces with Abcodia, the biomarker validation company with a focus on cancer screening, to develop new blood tests to detect a range of cancers when they are still at a very early stage. CANCER RESEARCH UK and its commercial arm, Cancer Research Technology (CRT), have joined forces with Abcodia, the biomarker validation company with a focus on cancer screening, to develop new blood tests to detect a range of cancers when they are still at a very early stage.

6 June 2013

The Ј50M Pioneer Fund announces first investment to develop cancer drugs

The Cancer Research Technology Pioneer Fund CPF today has made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, to develop a promising class of drugs called MPS1 inhibitors to treat cancer. The Cancer Research Technology Pioneer Fund CPF today has made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, to develop a promising class of drugs called MPS1 inhibitors to treat cancer.

23 April 2013

Cancer Research Technology and The Institute of Cancer Research enter collaboration with Janssen to discover multiple myeloma drug

Cancer Research Technology the commercial arm of Cancer Research UK, and The Institute of Cancer Research, London, today announce a collaboration with Janssen Biotech, Inc., to discover a potential new multiple myeloma drug. Cancer Research Technology the commercial arm of Cancer Research UK, and The Institute of Cancer Research, London, today announce a collaboration with Janssen Biotech, Inc., to discover a potential new multiple myeloma drug.

21 March 2013

Cancer Research Technology and AstraZeneca expand successful multi-project cancer metabolism alliance

Cancer Research Technology and AstraZeneca expand successful multi-project cancer metabolism alliance Cancer Research Technology and AstraZeneca expand successful multi-project cancer metabolism alliance

7 March 2013

Alliance of translational research centres established to accelerate global drug development

Six of the world's top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines. Six of the world's top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines.

21 January 2013

• Health & Medicine

Cancer Research UK and Lorus to co-develop first-of-kind drug, IL-17E, to treat solid tumours

Cancer Research UK’s Drug Development Office; Cancer Research Technology, the charity's commercial arm; and biopharmaceutical company, Lorus Therapeutics Inc., have partnered to take a new therapy with the potential to treat solid tumours, into its first clinical trial. Cancer Research UK’s Drug Development Office; Cancer Research Technology, the charity's commercial arm; and biopharmaceutical company, Lorus Therapeutics Inc., have partnered to take a new therapy with the potential to treat solid tumours, into its first clinical trial.

27 November 2012

Strategic Drug Discovery Alliance signed by CRT, Astex Pharmaceuticals and Newcastle University

Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and Newcastle University have signed a major five-year strategic drug discovery alliance. The partners will discover and develop new cancer drugs in collaboration with researchers at the Cancer Research UK Drug Discovery Program at the Northern Institute for Cancer Research (NICR, Newcastle University). Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and Newcastle University have signed a major five-year strategic drug discovery alliance. The partners will discover and develop new cancer drugs in collaboration with researchers at the Cancer Research UK Drug Discovery Program at the Northern Institute for Cancer Research (NICR, Newcastle University).

29 October 2012

Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research announce epigenetic drug discovery collaboration

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need. Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

7 September 2012